In the Media Tag: Colin Howden

RedHill Biopharma Presents New Data from Talicia®’s Phase 3 Studies at ACG 2020 Focused on Achieving Successful First-Line Treatment in H. pylori Eradication

In the Media Icon

RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that new data supporting the use of Talicia®1 as a first-line therapy for eradication of H. pylori in adults was presented at the American College of Gastroenterology (ACG) 2020 Virtual Annual Scientific Meeting. The Company also presented data highlighting the… Read More

No evidence for link between PPIs and dementia

In the Media Icon

Researchers found no clinically meaningful association between short-term proton pump inhibitor therapy and increased risk for dementia, according to the results of a meta-analysis. Colin W. Howden, MD, FACG, Hyman Professor of Medicine and chief of the division of gastroenterology at the University of Tennessee Health Science Center, and colleagues wrote that proton pump inhibitors… Read More

RedHill Biopharma Announces FDA Approval of Talicia® for Treatment of H. pylori in Adults

In the Media Icon

RedHill Biopharma Ltd.,  a specialty biopharmaceutical company primarily focused on the development and commercialization of proprietary drugs for the treatment of gastrointestinal diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved Talicia® (omeprazole magnesium, amoxicillin and rifabutin) delayed-release capsules 10 mg1/250 mg/12.5 mg for the treatment of Helicobacter pylori (H. pylori)… Read More